These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 7911760

  • 1. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA, Hofland LJ, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SW.
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [Abstract] [Full Text] [Related]

  • 2. Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide.
    Breeman WA, Hofland LJ, Bakker WH, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Kwekkeboom DJ, Visser TJ, Lamberts SW.
    Eur J Nucl Med; 1993 Nov; 20(11):1089-94. PubMed ID: 7904561
    [Abstract] [Full Text] [Related]

  • 3. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW.
    Life Sci; 1991 Nov; 49(22):1583-91. PubMed ID: 1658515
    [Abstract] [Full Text] [Related]

  • 4. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M.
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [Abstract] [Full Text] [Related]

  • 5. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, Kooij PP, Bruns C, van Hagen PM, Marbach P.
    Life Sci; 1991 Nov; 49(22):1593-601. PubMed ID: 1658516
    [Abstract] [Full Text] [Related]

  • 6. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ.
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
    Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ.
    J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
    [Abstract] [Full Text] [Related]

  • 8. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
    Breeman WA, van Hagen PM, Kwekkeboom DJ, Visser TJ, Krenning EP.
    Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
    de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Béhé M, Powell P, Mäcke HR.
    Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM, Stolz B, Albert R, Ruser G, Briner U, Mäcke HR, Bruns C.
    Nucl Med Biol; 1998 Apr; 25(3):181-8. PubMed ID: 9620621
    [Abstract] [Full Text] [Related]

  • 15. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
    Janson ET, Westlin JE, Eriksson B, Ahlström H, Nilsson S, Oberg K.
    Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
    [Abstract] [Full Text] [Related]

  • 16. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F.
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [Abstract] [Full Text] [Related]

  • 17. Studies on radiolabeled somatostatin analogues in rats and in patients.
    Breeman WA, Bakker WH, De Jong M, Hofland LJ, Kwekkeboom DJ, Kooij PP, Visser TJ, Krenning EP.
    Q J Nucl Med; 1996 Sep; 40(3):209-20. PubMed ID: 8961800
    [Abstract] [Full Text] [Related]

  • 18. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
    Laznickova A, Laznicek M, Trejtnar F, Melicharova L, Suzuki KH, Akizawa H, Arano Y, Yokoyama A.
    Eur J Drug Metab Pharmacokinet; 2002 Sep; 27(1):37-43. PubMed ID: 11996325
    [Abstract] [Full Text] [Related]

  • 19. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, Schicha H.
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.